- Report
- February 2024
- 70 Pages
Russia
From €4218EUR$4,750USD£3,617GBP
- Report
- February 2024
- 70 Pages
Australia
From €4218EUR$4,750USD£3,617GBP
- Report
- February 2024
- 70 Pages
Japan
From €4218EUR$4,750USD£3,617GBP
- Report
- August 2023
- 75 Pages
North America
From €4218EUR$4,750USD£3,617GBP
- Report
- August 2023
- 70 Pages
Latin America
From €4218EUR$4,750USD£3,617GBP
- Report
- October 2022
- 70 Pages
Africa
From €4218EUR$4,750USD£3,617GBP
- Report
- May 2026
- 200 Pages
Canada
From €2476EUR$2,789USD£2,124GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2476EUR$2,789USD£2,124GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2476EUR$2,789USD£2,124GBP
- Report
- June 2025
- 400 Pages
Global
From €4394EUR$4,949USD£3,769GBP
- Report
- May 2025
- 300 Pages
Global
From €4394EUR$4,949USD£3,769GBP
- Report
- August 2024
- 150 Pages
Global
From €2476EUR$2,789USD£2,124GBP
- Report
- March 2026
- 136 Pages
France
From €2663EUR$2,999USD£2,284GBP
€3551EUR$3,999USD£3,045GBP
- Report
- May 2024
- 140 Pages
Global
From €2663EUR$2,999USD£2,284GBP
€3551EUR$3,999USD£3,045GBP
- Report
- May 2024
- 213 Pages
Global
From €4435EUR$4,995USD£3,804GBP
- Report
- August 2026
- 160 Pages
From €2948EUR$3,320USD£2,528GBP
€3685EUR$4,150USD£3,160GBP
- Report
- August 2026
- 160 Pages
From €2948EUR$3,320USD£2,528GBP
€3685EUR$4,150USD£3,160GBP
- Report
- August 2026
- 160 Pages
From €2948EUR$3,320USD£2,528GBP
€3685EUR$4,150USD£3,160GBP
- Report
- August 2026
- 160 Pages
From €2948EUR$3,320USD£2,528GBP
€3685EUR$4,150USD£3,160GBP
- Report
- January 2025
- 140 Pages
Global
From €3507EUR$3,950USD£3,008GBP

The Sodium Dependent Glucose Co Transporter 2 (SGLT2) market is a subset of the Endocrine and Metabolic Disorders Drugs market. SGLT2 inhibitors are a class of drugs used to treat type 2 diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin effectively. These drugs work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to reduce blood glucose levels and improve glycemic control.
The SGLT2 market is highly competitive, with several major pharmaceutical companies offering products. These include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Merck, Novo Nordisk, and Sanofi. Each company offers a range of products, including both branded and generic versions. Show Less Read more